Table 1.

Descriptive Characteristics of Patients in the SAGhE Cohort Followed for Risk of Meningioma

Characteristic	No.	%
Sex
Male	5530	53.2
Female	4873	46.8
Country
Belgium	1325	12.7
Netherlands	1685	16.2
Sweden	2822	27.1
Switzerland	737	7.1
United Kingdom	3834	36.9
Age started GH treatment, y
0–4	1130	10.9
5–9	3632	34.9
10–14	4834	46.5
15–19	807	7.8
Year started GH treatment
<1990	2070	19.9
1990–1994	3976	38.2
1995–1999	2840	27.3
≥2000	1517	14.6
Diagnosis leading to GH treatment
CNS tumor	1307	12.6
Non-CNS solid tumor	97	0.9
Hematological malignancy	426	4.1
Chronic renal failure and renal diseases	139	1.3
Turner syndrome	1721	16.5
Other syndromes and chronic diseases	1003	9.6
Multiple pituitary hormone deficiency organic	1343	12.9
Skeletal dysplasias	286	2.8
Isolated growth failurea	3952	38.0
Nonclassifiable	129	1.2
Total	10,403	100.0

^aIncluding isolated GH deficiency, idiopathic short stature, and small for gestational age.